The DOI matches its Crossref record.
A Randomized Multicenter Trial of Crotalinae Polyvalent Immune Fab (Ovine) Antivenom for the Treatment for Crotaline Snakebite in the United States
Abstract
BACKGROUND: Current therapy for crotaline snakebite includes antivenin (Crotalidae) polyvalent, an antivenom with numerous adverse effects. We compared the efficacy and safety of 2 dosing regimens with a new antivenom, Crotalinae polyvalent immune Fab (Fab AV). METHODS: A single dose of Fab AV alone (as-needed [PRN] group) was compared with an initial dose plus repeated treatments during 18 hours (scheduled group) in a multicenter randomized trial. The study included patients with minimal or moderate envenomation by a crotaline snake within the preceding 6 hours, aged 10 years or older, in whom worsening of the envenomation syndrome was observed before Fab AV treatment. After treatment with Fab AV to achieve initial control, patients were randomized to the scheduled or PRN treatment group. Scheduled group patients received additional doses of Fab AV every 6 hours for 3 doses. The PRN group received no planned additional doses of antivenom. RESULTS: The mean severity score of the 31 patients decreased from 4.35 to 2.39 points (P<.001); there was no difference between scheduled and PRN groups. No patient in the scheduled group received unplanned Fab AV doses, but 8 of 16 patients in the PRN group received unplanned doses (P =.002). Acute reactions occurred in 6 patients (19%), and serum sickness occurred in 6 (23%) of 26 patients who returned for follow-up. CONCLUSIONS: In the first randomized trial of antivenom in the United States, Fab AV effectively terminated venom effects. Since the unplanned use of Fab AV in the PRN group was common, the treatment regimen may require more than 1 initial dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gold, B. S., Dart, R. C., & Barish, R. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra013477 · Cited by 466
Self-citationAdverse reactions to snake antivenom, and their prevention and treatment
de Silva, H. A., Ryan, N. M., & de Silva, H. J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12739 · Cited by 271
Tarcha, E. J., Chi, V., Muñoz-Elías, E. J., Bailey, D., Londono, L. M., Upadhyay, S. K., Norton, K., Banks, A., Tjong, I., Nguyen, H., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.191890 · Cited by 117
Snake Antivenoms—Toward Better Understanding of the Administration Route
Gamulin, E., Mateljak Lukačević, S., Halassy, B., & Kurtović, T. (2023) · Toxins · doi:10.3390/toxins15060398 · Cited by 30
Metadata
- Authors
- Dart, R. C., Seifert, S. A., Boyer, L. V., Clark, R. F., Hall, E., McKinney, P., McNally, J., Kitchens, C. S., Curry, S. C., Bogdan, G. M., Ward, S. B., & Porter, R. S.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2001-09-10
- Volume
- 161
- Issue
- 16
- Pages
- 2030
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2128425068
- Cited by
- 221
- References
- 0
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Multicenter Trial of Crotalinae Polyvalent Immune Fab (Ovine) Antivenom for the Treatment for Crotaline Snakebite in the United States. https://app.cochat.ai/papers/10.1001/archinte.161.16.2030
- The paper
- Dart, R. C., Seifert, S. A., Boyer, L. V., Clark, R. F., Hall, E., McKinney, P., McNally, J., Kitchens, C. S., Curry, S. C., Bogdan, G. M., Ward, S. B., & Porter, R. S. (2001). A Randomized Multicenter Trial of Crotalinae Polyvalent Immune Fab (Ovine) Antivenom for the Treatment for Crotaline Snakebite in the United States. Archives of Internal Medicine. https://doi.org/10.1001/archinte.161.16.2030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.